Alnylam Announces 33% Staff Cut, Will Focus Internally On Two Lead RNAi Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.